microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Childhood acute lymphoblastic leukemia (cALL) is a significant pediatric cancer.
• MicroRNAs play crucial roles in cancer development and progression.
• Understanding the molecular mechanisms underlying cALL is vital for developing targeted therapies.

Purpose of the Study:

• To investigate the role of microRNA-155-5p (miR-155-5p) in childhood ALL (cALL).
• To elucidate the interactions between miR-155-5p, casitas B-lineage lymphoma (CBL), interferon regulatory factor 4 (IRF4), and cyclin-dependent kinase 6 (CDK6) in cALL.
• To explore the therapeutic potential of targeting this pathway.

Main Methods:

• Bioinformatic analysis to identify differentially expressed genes in cALL.
• RT-qPCR and Western blot assays to quantify gene and protein expression levels.
• Dual-luciferase reporter gene assay to confirm miR-155-5p targeting of CBL.
• Cell proliferation (CCK-8) and apoptosis assays (flow cytometry) in ALL cells.
• Co-immunoprecipitation (Co-IP) to study protein interactions and ubiquitination.
• In vivo xenograft tumor models in nude mice for validation.

Main Results:

• miR-155-5p and CDK6 were upregulated, while CBL was downregulated in cALL samples.
• miR-155-5p directly targets and inhibits CBL expression.
• miR-155-5p promotes ALL cell proliferation and inhibits apoptosis by downregulating CBL.
• CBL normally degrades IRF4 via ubiquitination, inhibiting CDK6 expression; miR-155-5p disrupts this.
• In vivo studies confirmed that miR-155-5p promotes cALL development.

Conclusions:

• miR-155-5p promotes cALL development by targeting CBL.
• The miR-155-5p/CBL/IRF4/CDK6 axis is a key regulatory pathway in cALL.
• Targeting miR-155-5p or its downstream effectors may offer novel therapeutic strategies for cALL.